Although pTau and Aβ are the most commonly used blood biomarkers for assessing amyloid pathologies and tauopathies in Alzheimer’s disease, recent studies have identified GFAP as a reliable alternative and potentially more sensitive indicator of pathological states. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.